Biomarkers of Tretinoin Precursors and Tretinoin Efficacy in Patients with Moderate to Severe Facial Photodamage: A Randomized Clinical Trial

Keyphrases

• Moderate to Severe 100%
• Randomized Clinical Trial 100%
• Tretinoin 100%
• Messenger RNA (mRNA) 50%
• Matrix metalloproteinase-2 (MMP-2) 40%
• No Significant Difference 20%
• Retinol 20%
• Retinoids 20%
• Clinical Efficacy 20%
• Quantitative PCR 10%
• Over-the-counter 10%
• Topical Application 10%
• White Women 10%
• Clinical Benefit 10%
• Erythema 10%
• Procollagen I 10%
• Retinyl Palmitate 10%
• Strong Correlation 10%
• Referral Center 10%
• Potential Biomarkers 10%
• Tolerability 10%
• Randomized Double-blind 10%
• Target Gene Expression 10%
• Type IV Collagen 10%
• Dermatologist 10%
• Trial Registration 10%
• Single Center 10%
• Patient-reported Outcomes 10%
• Clinical Improvement 10%
• Mechanistic Studies 10%
• Matrix metalloproteinase-1 (MMP-1) 10%
• Griffith 10%
• Retinoic Acid Signaling 10%
• Retinyl Acetate 10%
• Ester Derivatives 10%
• CRABP2 10%
• Molecular Effects 10%
• Target Gene Analysis 10%
• Topical Formulation 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Biological Marker 100%
• Randomized Clinical Trial 100%
• Retinoic Acid 100%
• Gelatinase A 29%
• Retinoid 11%
• Retinol 11%
• Erythema 5%
• Retinol Palmitate 5%
• Tolerability 5%
• Interstitial Collagenase 5%
• Retinoic Acid Receptor 5%
• Retinol Acetate 5%
• Ester Derivative 5%
• Procollagen 5%

Medicine and Dentistry

• Photoaging 23%
• Ester Derivative 5%
• Retinol Palmitate 5%
• Retinol Acetate 5%